Ramipril Dosing and Management for Hypertension and Heart Failure

Introduction to Ramipril Guidelines

The American College of Cardiology/American Heart Association (ACC/AHA) suggests starting ramipril at 2.5 mg twice daily and titrating to 5 mg twice daily as tolerated for patients with anterior infarction, post-MI LV systolic dysfunction (EF ≤0.40), or heart failure 1

Check baseline renal function, potassium, and blood pressure before initiation, then recheck potassium and creatinine after 5-7 days, and after each dose increase 2
Monitor blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment 2
Follow-up at 3 months, then every 6 months thereafter 2
Creatinine increase up to 50% above baseline, or to a certain level, whichever is greater, is acceptable 3
Small increases in blood urea nitrogen and creatinine are expected and do not require discontinuation 3
Potassium levels up to a certain threshold are acceptable 3

Avoid NSAIDs and COX-2 inhibitors as they worsen renal function and reduce ACE inhibitor efficacy 2
Avoid potassium-sparing diuretics during initiation unless specifically needed for persistent hypokalemia 2
Avoid in hypotension, renal failure, and hyperkalemia 1

Aim for <130/80 mmHg in patients with hypertension and stable ischemic heart disease 2
For patients with chronic kidney disease (CKD) stage 3 or higher, or stage 1-2 with albuminuria, target <130/80 mmHg 5

Higher doses of ramipril provide superior outcomes, with a 22% reduction in MI, stroke, or CV death over 5 years in high-risk patients 2
The ATLAS trial demonstrated better outcomes with higher captopril doses, suggesting the same principle applies to ramipril 4